The availability of potent small-molecule drug-like GLO1 inhibitors currently used as pre-clinical therapeutics might also provide a powerful tool supporting mechanistic and clinical studies targeting GLO1 in PCa animal models and patients [48]. The gene discussed is GLO1; the disease is posterior cortical atrophy.